Regina Barnett
Family Medicine · Winterset, IANPI 1346706421
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 344 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,217 and has fallen 88.8% since, to $248 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$399
- Pfizer$374
- Amgen$357
- Bayer$290
- Otsuka America Pharmaceutical, Inc.$275
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,38499%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 88 | $1,236 |
| Boehringer Ingelheim | 23 | $399 |
| Pfizer | 22 | $374 |
| Amgen | 30 | $357 |
| Bayer | 14 | $290 |
| Otsuka America Pharmaceutical, Inc. | 9 | $275 |
| Lilly USA, LLC | 17 | $244 |
| Mylan Specialty L.p. | 14 | $224 |
| AstraZeneca | 12 | $200 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $163 |
| Biohaven Pharmaceuticals, Inc. | 11 | $151 |
| GSK | 10 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $127 |
| Astellas Pharma US Inc | 5 | $122 |
| Novartis | 7 | $110 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Novo Nordisk | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Nestle Healthcare Nutrition Inc. | 6 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Idorsia Pharmaceuticals US Inc | 5 | $87 |
| Lundbeck LLC | 5 | $80 |
| Kowa Pharmaceuticals America, Inc. | 5 | $70 |
| Merck | 5 | $64 |
| Abbott | 1 | $40 |
| Johnson & Johnson | 3 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Corium, LLC | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| GE HealthCare | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Bioventus LLC | 1 | $13 |
| Pharming Healthcare, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$121
How this compares
$5,446 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,132 |
| JardianceEmpagliflozin | 37 | $30,722 |
| MounjaroTirzepatide | 25 | $26,074 |
| OzempicSemaglutide | 21 | $21,346 |
| XareltoRivaroxaban | 16 | $18,577 |
| EliquisApixaban | 11 | $10,046 |
| Nucynta ErTapentadol Hcl | 12 | $3,939 |
| NucyntaTapentadol Hcl | 12 | $3,764 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,231 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,879 |
| Atorvastatin Calcium | 162 | $1,745 |
| Aripiprazole | 21 | $1,649 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $1,179 |
| Potassium Chloride | 40 | $936 |
| Lisinopril | 107 | $882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $141 | $34,01250 claims |
| Boehringer IngelheimJardiance | $399 | $30,72237 claims |
| Lilly USA, LLCMounjaro | $244 | $26,07425 claims |
| Novo NordiskOzempic | $100 | $21,34621 claims |
| Johnson & JohnsonXarelto | $40 | $18,57716 claims |
| PfizerEliquis | $374 | $10,04611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Winterset
- Kevin DeregnierWinterset$68K
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.